{"id":980382,"date":"2026-07-09T16:08:42","date_gmt":"2026-07-09T20:08:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/"},"modified":"2026-07-09T16:08:42","modified_gmt":"2026-07-09T20:08:42","slug":"neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/","title":{"rendered":"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <b>Conference Call and Webcast Scheduled for Thursday, July 30<\/b>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\">SAN DIEGO<\/span>, <span class=\"legendSpanClass\">July 9, 2026<\/span> \/PRNewswire\/ &#8212; Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2757001\" title=\"\" alt=\"\" \/>\n        <\/p>\n<\/p><\/div>\n<p>The schedule for the press release and conference call \/ webcast is as follows:<\/p>\n<ul type=\"disc\">\n<li>Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT \/ 4:00 p.m. ET<\/li>\n<li>Q2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT \/ 4:30 p.m. ET<\/li>\n<li>Domestic Dial-In Number: 800-347-6865<\/li>\n<li>International Dial-In Number: 203-518-9757<\/li>\n<li>Conference ID: NBIX<\/li>\n<\/ul>\n<p>The webcast can also be accessed on Neurocrine Biosciences&#8217; website under Investors at <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4728498-1&amp;h=872769439&amp;u=http%3A%2F%2Fwww.neurocrine.com%2F&amp;a=www.neurocrine.com\" target=\"_blank\" rel=\"nofollow\">www.neurocrine.com<\/a>. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.<\/p>\n<p>\n        <b><br \/>\n          <u>About Neurocrine Biosciences<br \/><\/u><br \/>\n        <\/b>Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company&#8217;s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington&#8217;s disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,*\u00a0as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4728498-1&amp;h=2069664683&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4450443-1%26h%3D3502828688%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4252873-1%2526h%253D4039787179%2526u%253Dhttps%25253A%25252F%25252Fwww.neurocrine.com%25252F%2526a%253Dneurocrine.com%26a%3Dneurocrine.com&amp;a=neurocrine.com\" target=\"_blank\" rel=\"nofollow\">neurocrine.com<\/a>, and follow the company on <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4728498-1&amp;h=3476018015&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4450443-1%26h%3D884458364%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4252873-1%2526h%253D928986078%2526u%253Dhttps%25253A%25252F%25252Fwww.linkedin.com%25252Fcompany%25252Fneurocrine-biosciences%2526a%253DLinkedIn%26a%3DLinkedIn&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4728498-1&amp;h=1301364348&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4450443-1%26h%3D1730331693%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4252873-1%2526h%253D3255611529%2526u%253Dhttps%25253A%25252F%25252Ftwitter.com%25252Fneurocrine%2526a%253DX%252B(formerly%252BTwitter)%26a%3DX&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>,\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4728498-1&amp;h=3151439303&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4450443-1%26h%3D3526407131%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D4252873-1%2526h%253D1536396415%2526u%253Dhttps%25253A%25252F%25252Fwww.facebook.com%25252FNeurocrine%2526a%253DFacebook%26a%3DFacebook&amp;a=Facebook\" target=\"_blank\" rel=\"nofollow\">Facebook<\/a>\u00a0and\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4728498-1&amp;h=790568981&amp;u=https%3A%2F%2Fwww.youtube.com%2F%40NeurocrineBiosciencesInc&amp;a=YouTube\" target=\"_blank\" rel=\"nofollow\">YouTube<\/a>. (<i>*in collaboration with AbbVie<\/i>)\u00a0\u00a0<\/p>\n<p>NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA01282&amp;sd=2026-07-09\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results-302822071.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results-302822071.html<\/a><\/p>\n<p>SOURCE Neurocrine Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA01282&amp;Transmission_Id=202607091601PR_NEWS_USPR_____LA01282&amp;DateId=20260709\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 \/PRNewswire\/ &#8212; Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026. The schedule for the press release and conference call \/ webcast is as follows: Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT \/ 4:00 p.m. ET Q2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT \/ 4:30 p.m. ET Domestic Dial-In Number: 800-347-6865 International Dial-In Number: 203-518-9757 Conference ID: NBIX The webcast can also be accessed on Neurocrine Biosciences&#8217; website under Investors at &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-980382","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 \/PRNewswire\/ &#8212; Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026. The schedule for the press release and conference call \/ webcast is as follows: Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT \/ 4:00 p.m. ET Q2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT \/ 4:30 p.m. ET Domestic Dial-In Number: 800-347-6865 International Dial-In Number: 203-518-9757 Conference ID: NBIX The webcast can also be accessed on Neurocrine Biosciences&#8217; website under Investors at &hellip; Continue reading &quot;Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-09T20:08:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2757001\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results\",\"datePublished\":\"2026-07-09T20:08:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/\"},\"wordCount\":339,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS472708\\\/NRC-Logo-4C.jpg?id=OA2757001\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/\",\"name\":\"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS472708\\\/NRC-Logo-4C.jpg?id=OA2757001\",\"datePublished\":\"2026-07-09T20:08:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS472708\\\/NRC-Logo-4C.jpg?id=OA2757001\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS472708\\\/NRC-Logo-4C.jpg?id=OA2757001\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - Market Newsdesk","og_description":"PR Newswire Conference Call and Webcast Scheduled for Thursday, July 30 SAN DIEGO, July 9, 2026 \/PRNewswire\/ &#8212; Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2026. The schedule for the press release and conference call \/ webcast is as follows: Q2 2026 Press Release: July 30, 2026 at 1:00 p.m. PT \/ 4:00 p.m. ET Q2 2026 Conference Call: July 30, 2026 at 1:30 p.m. PT \/ 4:30 p.m. ET Domestic Dial-In Number: 800-347-6865 International Dial-In Number: 203-518-9757 Conference ID: NBIX The webcast can also be accessed on Neurocrine Biosciences&#8217; website under Investors at &hellip; Continue reading \"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-09T20:08:42+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2757001","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results","datePublished":"2026-07-09T20:08:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/"},"wordCount":339,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2757001","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/","name":"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2757001","datePublished":"2026-07-09T20:08:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2757001","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS472708\/NRC-Logo-4C.jpg?id=OA2757001"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2026-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=980382"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980382\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=980382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=980382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=980382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}